What is a stock summary page? Click here for an overview.
Business Description
AbCellera Biologics Inc
NAICS : 541714
SIC : 3741
ISIN : CA00288U1066
Share Class Description:
ABCL: Ordinary SharesCompare
Compare
Traded in other countries / regions
ABCL.USA8QQ.Germany Index Membership
Russell 3000Russell 2000 IPO Date
2020-12-11Description
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.57 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.32 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.75 | |||||
| Beneish M-Score | -2.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -56.4 | |||||
| 3-Year Book Growth Rate | -0.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -12.09 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 24.26 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.79 | |||||
| 9-Day RSI | 67.51 | |||||
| 14-Day RSI | 59.37 | |||||
| 3-1 Month Momentum % | -25.57 | |||||
| 6-1 Month Momentum % | -4.07 | |||||
| 12-1 Month Momentum % | -33.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.81 | |||||
| Quick Ratio | 9.81 | |||||
| Cash Ratio | 8.17 | |||||
| Days Sales Outstanding | 420.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 1.41 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1044.41 | |||||
| Net Margin % | -564.81 | |||||
| FCF Margin % | -648.37 | |||||
| ROE % | -14.73 | |||||
| ROA % | -11.44 | |||||
| ROIC % | -36.03 | |||||
| 3-Year ROIIC % | -212.14 | |||||
| ROC (Joel Greenblatt) % | -94.75 | |||||
| ROCE % | -22.59 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 26.42 | |||||
| PB Ratio | 0.73 | |||||
| Price-to-Tangible-Book | 0.8 | |||||
| EV-to-EBIT | -0.65 | |||||
| EV-to-Forward-EBIT | -1.71 | |||||
| EV-to-EBITDA | -0.96 | |||||
| EV-to-Forward-EBITDA | -1.93 | |||||
| EV-to-Revenue | 6.82 | |||||
| EV-to-Forward-Revenue | 8.29 | |||||
| EV-to-FCF | -1.05 | |||||
| Price-to-GF-Value | 2.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.72 | |||||
| Price-to-Net-Cash | 2.39 | |||||
| Earnings Yield (Greenblatt) % | -153.85 | |||||
| FCF Yield % | -24.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABCL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AbCellera Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 28.834 | ||
| EPS (TTM) ($) | -0.55 | ||
| Beta | 0.88 | ||
| 3-Year Sharpe Ratio | -0.73 | ||
| 3-Year Sortino Ratio | -0.93 | ||
| Volatility % | 45.55 | ||
| 14-Day RSI | 59.37 | ||
| 14-Day ATR ($) | 0.170749 | ||
| 20-Day SMA ($) | 2.29 | ||
| 12-1 Month Momentum % | -33.59 | ||
| 52-Week Range ($) | 1.8906 - 4.33975 | ||
| Shares Outstanding (Mil) | 297.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AbCellera Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AbCellera Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AbCellera Biologics Inc Frequently Asked Questions
What is AbCellera Biologics Inc(ABCL)'s stock price today?
The current price of ABCL is $2.60. The 52 week high of ABCL is $4.34 and 52 week low is $1.89.
When is next earnings date of AbCellera Biologics Inc(ABCL)?
The next earnings date of AbCellera Biologics Inc(ABCL) is 2025-05-08.
Does AbCellera Biologics Inc(ABCL) pay dividends? If so, how much?
AbCellera Biologics Inc(ABCL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers